2026 ICD-10-CM Diagnosis Code T46.6X2APoisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter
T46.6X2A is a billable ICD-10-CM diagnosis code for poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter. The 7th character A marks it as an initial encounter code, used while the patient is receiving active treatment. It is valid on HIPAA claims for fiscal year 2026 (October 1, 2025 through September 30, 2026) and groups to MS-DRG 917 through 918. Coders also document this condition as clofibrate overdose. In AHRQ's Clinical Classifications Software (CCSR), this diagnosis falls under External cause codes: intent of injury, self-harm; External cause codes: poisoning by drug; and Poisoning by drugs, initial encounter.
Code Identity
Code Classification
Approximate SynonymsGuidance
Alternate terms and clinical phrases that map to this code.
- Clofibrate overdose
- Gamolenic acid overdose
- Intentional clofibrate overdose
- Intentional clofibrate poisoning
- Intentional gamolenic acid overdose
- Poisoning by clofibrate
Coding GuidelinesGuidance
When coding a poisoning or reaction to the improper use of a medication (e.g., overdose, wrong substance given or taken in error, wrong route of administration), first assign the appropriate code from categories T36-T50. The poisoning codes have an associated intent as their 5th or 6th character (accidental, intentional self-harm, assault and undetermined). If the intent of the poisoning is unknown or unspecified, code the intent as accidental intent. The undetermined intent is only for use if the documentation in the record specifies that the intent cannot be determined. Use additional code(s) for all manifestations of poisonings.
The appropriate 7th character is to be added to each code from block Poisoning by, adverse effect of and underdosing of agents primarily affecting the cardiovascular system (T46). Use the following options for the applicable episode of care:
- A - initial encounter
- D - subsequent encounter
- S - sequela
Source: ICD-10-CM Official Guidelines for Coding and Reporting, FY 2026, published by CMS and the National Center for Health Statistics.
Clinical ClassificationClinical
AHRQ’s CCSR groups this code into broader clinical categories.
Clinical InformationClinical
Bezafibrate
an antilipemic agent that lowers cholesterol and triglycerides. it decreases low density lipoproteins and increases high density lipoproteins.Clofibrate
a fibric acid derivative used in the treatment of hyperlipoproteinemia type iii and severe hypertriglyceridemia. (from martindale, the extra pharmacopoeia, 30th ed, p986)Colestipol
highly crosslinked and insoluble basic anion exchange resin used as anticholesteremic. it may also may reduce triglyceride levels.Fenofibrate
an antilipemic agent which reduces both cholesterol and triglycerides in the blood.Gemfibrozil
a lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.Halofenate
an antihyperlipoproteinemic agent and uricosuric agent.Linoleic Acid
a doubly unsaturated fatty acid, occurring widely in plant glycosides. it is an essential fatty acid in mammalian nutrition and is used in the biosynthesis of prostaglandins and cell membranes. (from stedman, 26th ed)Linoleic Acids
eighteen-carbon essential fatty acids that contain two double bonds.Linoleic Acids, Conjugated
a collective term for a group of around nine geometric and positional isomers of linoleic acid in which the trans/cis double bonds are conjugated, where double bonds alternate with single bonds.Linoleoyl-CoA Desaturase
an enzyme that catalyzes the syn-dehydrogenation of linoleol-coa gamma-linolenoyl-coa. it was formerly characterized as ec 1.14.99.25.Lovastatin
a fungal metabolite isolated from cultures of aspergillus terreus. the compound is a potent anticholesteremic agent. it inhibits 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it also stimulates the production of low-density lipoprotein receptors in the liver.Oleic Acid
an unsaturated fatty acid that is the most widely distributed and abundant fatty acid in nature. it is used commercially in the preparation of oleates and lotions, and as a pharmaceutical solvent. (stedman, 26th ed)Oleic Acids
a group of fatty acids that contain 18 carbon atoms and a double bond at the omega 9 carbon.Ricinoleic Acids
eighteen carbon fatty acids that comprise the great majority of castor oil, which is from the seed of ricinus.Pravastatin
an antilipemic fungal metabolite isolated from cultures of nocardia autotrophica. it acts as a competitive inhibitor of hmg coa reductase (hydroxymethylglutaryl coa reductases).Probucol
a drug used to lower ldl and hdl cholesterol yet has little effect on serum-triglyceride or vldl cholesterol. (from martindale, the extra pharmacopoeia, 30th ed, p993).Safflower Oil
an oily liquid extracted from the seeds of the safflower, carthamus tinctorius. it is used as a dietary supplement in the management of hypercholesterolemia. it is used also in cooking, as a salad oil, and as a vehicle for medicines, paints, varnishes, etc. (dorland, 28th ed & random house unabridged dictionary, 2d ed)Simvastatin
a derivative of lovastatin and potent competitive inhibitor of 3-hydroxy-3-methylglutaryl coenzyme a reductase (hydroxymethylglutaryl coa reductases), which is the rate-limiting enzyme in cholesterol biosynthesis. it may also interfere with steroid hormone production. due to the induction of hepatic ldl receptors, it increases breakdown of ldl cholesterol.Sitosterols
a family of sterols commonly found in plants and plant oils. alpha-, beta-, and gamma-isomers have been characterized.Triparanol
antilipemic agent with high ophthalmic toxicity. according to merck index, 11th ed, the compound was withdrawn from the market in 1962 because of its association with the formation of irreversible cataracts.
Table of Drugs and ChemicalsClinical
Substances in the Table of Drugs and Chemicals that reference this code family. Always confirm in the Tabular List before coding.
Patient EducationClinical
Poisoning
A poison is any substance that is harmful to your body. You might swallow it, inhale it, inject it, or absorb it through your skin. Any substance can be poisonous if too much is taken. Poisons can include:
Read the full article at MedlinePlus
Courtesy of MedlinePlus, a service of the U.S. National Library of Medicine.
Convert T46.6X2A to ICD-9-CMHistory
The closest ICD-9-CM equivalents under the General Equivalence Mappings.
Code HistoryHistory
Questions About T46.6X2AOverview
Is T46.6X2A a billable code?
Yes. This is a billable ICD-10-CM code, specific enough to report poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter on HIPAA-covered claims from October 1, 2025 through September 30, 2026.
What does the 7th character A in T46.6X2A mean?
The final character A marks the initial encounter: use it while the patient is receiving active treatment for poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, such as an emergency visit or first evaluation.
What MS-DRG does T46.6X2A group to?
When poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter is the principal diagnosis on an inpatient stay, it groups to MS-DRG 917, 918, with relative weights from 0.8571 to 1.5684 depending on complications. Higher weights mean higher Medicare reimbursement.
What is the ICD-9 equivalent of T46.6X2A?
Under the General Equivalence Mappings, poisoning by antihyperlipidemic and antiarteriosclerotic drugs, intentional self-harm, initial encounter converts to ICD-9-CM 972.2 (poisoning-antilipemics) and E950.4 (poison-drug/medicin NEC). The mapping is approximate, so confirm the match fits the documentation.
Footnotes
[1] Not chronic - A diagnosis code that does not fit the criteria for chronic condition (duration, ongoing medical treatment, and limitations) is considered not chronic. Some codes designated as not chronic are acute conditions. Other diagnosis codes that indicate a possible chronic condition, but for which the duration of the illness is not specified in the code description (i.e., we do not know the condition has lasted 12 months or longer) also are considered not chronic.
